Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system

Chemico-Biological Interactions

Volumn 187, Issue 1-3, 2010, Pages 295-298

  Gaydess, Andrea ^a   Duysen, Ellen ^b   Li, Yuan ^a   Gilman, Vladimir ^c   Kabanov, Alexander ^a   Lockridge, Oksana ^b   Bronich, Tatiana ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c INFOSCITEX CORPORATION   (United States)

Author keywords

Block ionomer complexes; Butyrylcholinesterase; CNS drug delivery; Nanotechnology

Indexed keywords

C 1057; CHOLINESTERASE; MACROGOL; POLYLYSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; COMPLEX FORMATION; CONTROLLED STUDY; CROSS LINKING; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG LABELING; DRUG MIXTURE; DRUG STABILITY; DRUG STRUCTURE; IN VIVO STUDY; MOLECULAR IMAGING; MOLECULAR SIZE; MOUSE; NANOPHARMACEUTICS; NONHUMAN;

MUS;

EID: 77955514799     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.01.005     Document Type: Article

References (13)

1. Geula C., Nagykery N. Butyrylcholinesterase activity in the rat forebrain and upper brainstem: postnatal development and adult distribution. Exp. Neurol. 2007, 204(2):640-657.
2. Mehrani H. Protective effect of polyurethane immobilized human butyrylcholinesterase against parathion inhalation in rat. Environ. Toxicol. Pharmacol. 2004, 16(3):179-185.
3. Schumacher I., Arad A., Margalit R. Butyrylcholinesterase formulated in liposomes. Biotechnol. Appl. Biochem. 1999, 30(Pt 3):225-230.
4. Lockridge O., Bartels C.F., Vaughan T.A., Wong C.K., Norton S.E., Johnson L.L. Complete amino acid sequence of human serum cholinesterase. J. Biol. Chem. 1987, 262(2):549-557.
5. Nicolet Y., Lockridge O., Masson P., Fontecilla-Camps J.C., Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 2003, 278(42):41141-41147.
6. Altamirano C.V., Lockridge O. Association of tetramers of human butyrylcholinesterase is mediated by conserved aromatic residues of the carboxy terminus. Chem. Biol. Interact. 1999, 119-120:53-60.
7. Duysen E.G., Lockridge O. Whole body and tissue imaging of the butyrylcholinesterase knockout mouse injected with near infrared dye labeled butyrylcholinesterase. Chem. Biol. Interact. 2008, 175(1-3):119-124.
8. Johnson N.D., Duysen E.G., Lockridge O. Intrathecal delivery of fluorescent labeled butyrylcholinesterase to the brains of butyrylcholinesterase knock-out mice: visualization and quantification of enzyme distribution in the brain. Neurotoxicology 2009, 30(3):386-392.
9. Vinogradov S.V., Batrakova E.V., Kabanov A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem. 2004, 15(1):50-60.
10. Batrakova E.V., Bronich T.K., Vetro J.A., Kabanov A.V. Polymer micelles as drug carriers. Nanoparticulates as Drug Carriers 2006, 57-93. Imperial College Press, London. V.P. Torchilin (Ed.).
11. Karnovsky M.J., Roots L. A " Direct-Coloring" thiocholine method for cholinesterases. J. Histochem. Cytochem. 1964, 12:219-221.
12. Li B., Duysen E.G., Saunders T.L., Lockridge O. Production of the butyrylcholinesterase knockout mouse. J. Mol. Neurosci. 2006, 30(1-2):193-195.
13. Gutierrez E.G., Banks W.A., Kastin A.J. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J. Neuroimmunol. 1993, 47(2):169-176.